drugset

drugset / Trial / NCT02720536

Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation

NCT02720536 ↗

Phase 3 Completed 53 enrolled Novartis Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

Extend evaluation of deferasirox film-coated tablet (FCT) formulation

Timeline

Start: 2016-08-16
Primary completion: 2019-07-23
Completion: 2019-07-23

Publications

Tartaglione I, Origa R, Kattamis A, Pfeilstocker M, Gunes S, Crowe S, Fagan N, Vincenzi B, Ruffo GB. Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study. Exp Hematol Oncol. 2020 Aug 10;9:20. doi: 10.1186/s40164-020-00174-2. eCollection 2020.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Deferasirox	Unknown	90 mg	Oral
Subject	Deferasirox	Unknown	180 mg	Oral
Subject	Deferasirox	Unknown	360 mg	Oral

Indications